Fresenius SE & Co. KGaA (FRE) Given Buy Rating at Citigroup

Fresenius SE & Co. KGaA (FRA:FRE)‘s stock had its “buy” rating reiterated by investment analysts at Citigroup in a research note issued on Friday, December 1st.

A number of other analysts have also weighed in on the stock. DZ Bank reaffirmed a “buy” rating on shares of Fresenius SE & Co. KGaA in a research note on Monday, August 21st. Commerzbank set a €85.00 ($101.19) price target on shares of Fresenius SE & Co. KGaA and gave the company a “buy” rating in a report on Monday, September 18th. Morgan Stanley set a €83.00 ($98.81) price objective on shares of Fresenius SE & Co. KGaA and gave the company a “buy” rating in a research note on Wednesday, October 4th. Berenberg Bank set a €90.00 ($107.14) target price on shares of Fresenius SE & Co. KGaA and gave the stock a “buy” rating in a research report on Wednesday, September 20th. Finally, Deutsche Bank set a €85.00 ($101.19) price objective on shares of Fresenius SE & Co. KGaA and gave the stock a “buy” rating in a report on Tuesday, August 8th. Seven analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. Fresenius SE & Co. KGaA currently has an average rating of “Buy” and a consensus target price of €79.48 ($94.61).

Shares of Fresenius SE & Co. KGaA (FRA:FRE) opened at €67.09 ($79.87) on Friday. Fresenius SE & Co. KGaA has a 1 year low of €60.16 ($71.62) and a 1 year high of €80.00 ($95.24).

COPYRIGHT VIOLATION NOTICE: This article was originally posted by Week Herald and is the sole property of of Week Herald. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this article can be viewed at https://weekherald.com/2017/12/13/fresenius-se-co-kgaa-fre-earns-buy-rating-from-citigroup.html.

About Fresenius SE & Co. KGaA

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

Analyst Recommendations for Fresenius SE & Co. KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply